FDA Approves Freenome’s Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S.
ABT•FDA approves Freenome's blood-based CRC screening test
- FDA approves Freenome’s Simplescreen™ CRC blood-based screening test; Abbott to commercialize in the U.S.
- Freenome to receive $100 million milestone payment from Abbott for FDA approval
Related News
Masimo Receives FDA 510(K) Clearance For The Pediatric Patient State Index, The First-And-Only Sedation Score Specifically Designed For The Unique Physiology Of The Pediatric Brain
MASI•
Finance of America Expands Executive Team To Support Next Phase Of Growth
FOA•
